Skip to content

Normalizing CO2 in Chronic Hyperventilation by a Novel Breathing Mask: A Pilot Study

CO2 Rebreathing by a Partial Rebreathing Mask as a Treatment of Chronic Idiopathic Hyperventilation - a Pilot Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01575665
Acronym
HVMASKE
Enrollment
6
Registered
2012-04-11
Start date
2011-02-28
Completion date
2011-06-30
Last updated
2016-05-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Idiopathic Hyperventilation, Dysfunctional Breathing, Hyperventilation, Respiratory Alkalosis

Keywords

Hyperventilation, Chronic Idiopathic Hyperventilation, Dysfunctional Breathing, Respiratory Alkalosis, Respiratory Acidosis

Brief summary

Background: Chronic Idiopathic Hyperventilation (CIH) is a form of dysfunctional breathing which has proven hard to treat effectively. The investigators hypothesised that by periodically inducing normocapnia over several weeks, it would be possible to raise the normal resting level/set point of CO2 and achieve a reduction of symptoms. Methods: Six CIH patients were treated two hours a day for four weeks with a novel breathing mask. The mask was used to induce normocapnia in these chronically hypocapnic patients. Capillary blood gases (PcCO2, pH, Standard Base Excess (SBE) etc.) were measured at baseline and once each week at least three hours after mask use, as well as spirometric values, breath holding tolerance and hyperventilation symptoms as per the Nijmegen Questionnaire (NQ),.

Interventions

DEVICEPartial Rebreathing Mask

Inducing normal CO2 for two hours a day for four weeks

Sponsors

Rehaler
CollaboratorINDUSTRY
University of Aarhus
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

Chronic idiopathic hyperventilation, i.e.: * PCO2 level below 4.7 kPa AND * SBE value more negative than -1.0

Exclusion criteria

* Oxygen saturation of 95% or lower at rest

Design outcomes

Primary

MeasureTime frameDescription
Blood gas and acid/base statusOnce every week in the treatment period of four weekspH, PCO2, PO2, Standard Base Excess

Secondary

MeasureTime frameDescription
Hyperventilation symptomsonce a weekNijmegen Questionnaire
Breath Hold Toleranceonce a week
Spirometric valuesonce a weekFEV1, FVC

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026